Social
News Feature: Comparison of Three Coronavirus Vaccines
https://t.co/omxsA8W3nQ https://t.co/s7dc9NwMQo
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: Rheumatic Patients Are at Risk for COVID Death
https://t.co/bhJG1vuVA4 https://t.co/VEN3nwSOPB
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
REMDACTA trial of Actemra plus remdesivir failed to meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia (nor its key secondary endpoints) compared to remdesivir alone https://t.co/OyqpnwUVXU
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: Low Anaphylaxis Risk with COVID mRNA Vaccines
JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals.
https://t.co/hN7UWNasQo https://t.co/0UhOZuGze1
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
COVID Vaccine Rebuttals by Dr. Kathryn Dao ( @KDAO2011)
Dr. Dao addresses the common vaccine concerns that have been posed to her and her rebuttals.
https://t.co/f5gwBICEGy https://t.co/Nzm1HfY5GW
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: Low Anaphylaxis Risk with COVID mRNA Vaccines
JAMA reports a safety survey of hospital employees showing that the risk of anaphylaxis from mRNA vaccines is 2.47 per 10,000 individuals.
https://t.co/hN7UWNasQo https://t.co/pVlaTUSCH7
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: COVID-19-Related Deaths in Rheumatic Disease Patients
There is a growing body of evidence regarding COVID-19 outcomes (including death) in rheumatic disease patients...
https://t.co/N3SGTnTjsq https://t.co/Xlnt3oxKbo
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: CDC: Interim Guidance for COVID Vaccinated People
https://t.co/3GZDCVF0hv https://t.co/qyQyajjqM8
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
Data Safety committee has closed recruitment to the colchicine arm in the RECOVERY trial a UK study of outcomes in COVID-19. Among 11162 enrolled pts (2178 deaths) those Rx w/ Colchicine had same 28 day mortality as usual care (20% vs. 19%) https://t.co/8gUc8LAZTp
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
News Feature: Baricitinib Therapy in Covid-19 Pneumonia
https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 1 month ago
